Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 4/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24140916 | 0.80 | ALOX5 (0.35) | MAPTALDH1A1SMN1; SMN2ALOX5 | |
| SCHEMBL3720192 | 0.79 | HCAR3 (0.59) | MAPTNPSR1ALDH1A1HTTHCAR3 | |
| SCHEMBL11744600 | 0.77 | MAPT (0.64) | MAPTNPSR1ALDH1A1HTTHCAR3 | |
| SCHEMBL25877536 | 0.76 | KDM4E (0.44) | MAPTTDP1ALDH1A1HCAR3MAPK1 | |
| SCHEMBL25877846 | 0.76 | MAPT (0.38) | MAPTNPSR1TDP1ALDH1A1TSHR | |
| SCHEMBL585719 | 0.75 | MAPT (0.46) | MAPTNPSR1TDP1ALDH1A1TSHR | |
| SCHEMBL11877200 | 0.75 | ALDH1A1 (0.57) | MAPTNPSR1TDP1ALDH1A1TSHR | |
| SCHEMBL3719024 | 0.74 | HCAR3 (0.61) | MAPTNPSR1TDP1ALDH1A1TSHR | |
| SCHEMBL3722356 | 0.74 | HCAR3 (0.60) | MAPTNPSR1TDP1ALDH1A1HCAR3 | |
| SCHEMBL11744519 | 0.74 | TSHR (0.51) | MAPTNPSR1TDP1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2021263079-A1 | TREX1 INHIBITORS AND USES THEREOF | TEMPEST THERAPEUTICS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234943-A1 | TREX1 INHIBITORS AND USES THEREOF | FEN1, ERCC4, DCLRE1B | MAPT 3694/4885NPSR1 4798/4885TDP1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.